Astellas Pharma Forecast, price target & analysts
Astellas Pharma Target price 2026 - Analyst rating & recommendation
Astellas Pharma Classifications & Recommendation
Astellas Pharma Price Target
| Target Price | ¥2,504.10 |
| Price | ¥2,356.50 |
| Potential | |
| Number of Estimates | 17 |
| 17 Analysts have issued a price target Astellas Pharma 2027 . The average Astellas Pharma target price is ¥2,504.10. This is higher than the current stock price. The highest price target is , the lowest is . | |
| A rating was issued by 19 analysts: 7 Analysts recommend Astellas Pharma to buy, 11 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2027 of . Most analysts recommend the Astellas Pharma stock at Hold. |
Sales and Margin forecast 2027, 2028 & 2029
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? | |
| Net Margin | ??? | ??? |
| ??? | ??? |
16 Analysts have issued a sales forecast Astellas Pharma 2027 . The average Astellas Pharma sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
14 Analysts have issued an Astellas Pharma EBITDA forecast 2027. The average Astellas Pharma EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
16 Astellas Pharma Analysts have issued a net profit forecast 2027. The average Astellas Pharma net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2027, 2028 & 2029
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
Astellas Pharma...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
